MX2023013443A - Formas cocristalinas de un inhibidor de la tirosina cinasa de bruton. - Google Patents

Formas cocristalinas de un inhibidor de la tirosina cinasa de bruton.

Info

Publication number
MX2023013443A
MX2023013443A MX2023013443A MX2023013443A MX2023013443A MX 2023013443 A MX2023013443 A MX 2023013443A MX 2023013443 A MX2023013443 A MX 2023013443A MX 2023013443 A MX2023013443 A MX 2023013443A MX 2023013443 A MX2023013443 A MX 2023013443A
Authority
MX
Mexico
Prior art keywords
bruton
tyrosine kinase
kinase inhibitor
cocrystalline
cocrystalline forms
Prior art date
Application number
MX2023013443A
Other languages
English (en)
Inventor
David Andrew Coates
Lori Raquel Hilden
Original Assignee
Loxo Oncology Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Loxo Oncology Inc filed Critical Loxo Oncology Inc
Publication of MX2023013443A publication Critical patent/MX2023013443A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C55/00—Saturated compounds having more than one carboxyl group bound to acyclic carbon atoms
    • C07C55/02—Dicarboxylic acids
    • C07C55/14—Adipic acid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C61/00—Compounds having carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C61/06—Saturated compounds having a carboxyl group bound to a five-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Se proporcionan en la presente descripción formas cocristalinas que incluyen BTK-I útiles en el tratamiento y prevención de enfermedades que se pueden tratar con un inhibidor de BTK, incluidas las enfermedades y trastornos asociados con BTK, caracterizaciones y métodos de elaboración de estas formas cocristalinas.
MX2023013443A 2021-05-14 2022-05-11 Formas cocristalinas de un inhibidor de la tirosina cinasa de bruton. MX2023013443A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163188747P 2021-05-14 2021-05-14
PCT/US2022/028663 WO2022240920A1 (en) 2021-05-14 2022-05-11 Cocrystalline forms of a bruton's tyrosine kinase inhibitor

Publications (1)

Publication Number Publication Date
MX2023013443A true MX2023013443A (es) 2023-12-12

Family

ID=82019727

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023013443A MX2023013443A (es) 2021-05-14 2022-05-11 Formas cocristalinas de un inhibidor de la tirosina cinasa de bruton.

Country Status (11)

Country Link
US (1) US20240207229A1 (es)
EP (1) EP4337196A1 (es)
JP (1) JP2024517963A (es)
KR (1) KR20230171449A (es)
CN (1) CN117320712A (es)
AU (1) AU2022274771B2 (es)
BR (1) BR112023021235A2 (es)
CA (1) CA3217452A1 (es)
IL (1) IL308011A (es)
MX (1) MX2023013443A (es)
WO (1) WO2022240920A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024176164A1 (en) 2023-02-22 2024-08-29 Assia Chemical Industries Ltd. Solid state form of pirtobrutinib
WO2024179558A1 (zh) * 2023-03-02 2024-09-06 苏州科睿思制药有限公司 Pirtobrutinib的晶型及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9138436B2 (en) 2011-07-13 2015-09-22 Pharmacyclics Llc Inhibitors of Bruton's tyrosine kinase
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
US8957080B2 (en) 2013-04-09 2015-02-17 Principia Biopharma Inc. Tyrosine kinase inhibitors
US9637486B2 (en) 2013-12-20 2017-05-02 Merck Sharp & Dohme Corp. Btk inhibitors
SG11201606858RA (en) 2014-02-21 2016-09-29 Principia Biopharma Inc Salts and solid form of a btk inhibitor
HUE051921T2 (hu) 2015-12-16 2021-03-29 Loxo Oncology Inc Kináz inhibitorként alkalmas vegyületek
US20210260060A1 (en) 2018-07-20 2021-08-26 Merck Patent Gmbh A substituted amino-pyrimidine compound for use in a method for treatment and prevention of multiple sclerosis
CA3224945A1 (en) 2018-07-31 2020-02-06 Loxo Oncology, Inc. Spray-dried dispersions, formulations, and polymorphs of (s)-5-amino-3-(4-((5-fluoro-2-methoxybenzamido)methyl)phenyl)-1-(1,1,1-trifluoropropan-2-yl)-1h-pyrazole-4-carboxamide
JP2023520469A (ja) 2020-04-03 2023-05-17 ジェネンテック， インコーポレイテッド ブルトン型チロシンキナーゼの阻害剤を使用する再発性多発性硬化症の治療方法

Also Published As

Publication number Publication date
AU2022274771B2 (en) 2024-10-10
AU2022274771A1 (en) 2023-11-16
CN117320712A (zh) 2023-12-29
JP2024517963A (ja) 2024-04-23
IL308011A (en) 2023-12-01
CA3217452A1 (en) 2022-11-17
KR20230171449A (ko) 2023-12-20
BR112023021235A2 (pt) 2023-12-12
US20240207229A1 (en) 2024-06-27
EP4337196A1 (en) 2024-03-20
WO2022240920A1 (en) 2022-11-17

Similar Documents

Publication Publication Date Title
MX2023013443A (es) Formas cocristalinas de un inhibidor de la tirosina cinasa de bruton.
MX2022012992A (es) Inhibidores de kif18a para el tratamiento de enfermedades neoplasicas.
MX2020009773A (es) Terapia de combinacion.
ZA202212876B (en) 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of braf-associated diseases and disorders
ATE241375T1 (de) Verwendung eines serenoa repens extraktes zur herstellung eines arzneimittels zur behandlung von krebserkrankungen der prostata
ZA202202361B (en) Treatment of hidradenitis suppurativa using jak inhibitors
TW200731979A (en) RNAi-mediated inhibition of RHO kinase for treatment of ocular disorders
MX2021010058A (es) Formulaciones de rapamicina tópicas y su uso en el tratamiento de angiofibromas faciales y otros trastornos de la piel.
MX2019003134A (es) Terapia de combinacion.
MX2023002321A (es) Tratamiento de trastornos de perdida de cabello con inhibidores de cinasas asociadas a janus (jak) deuterados.
MX2022012952A (es) Inhibidor de ret cristalino.
MX2021011488A (es) Compuestos y usos de estos.
MX2008002456A (es) Uso de ambroxol para el tratamiento de infecciones por rinovirus.
MX2020009532A (es) Oligonucleotidos modificados para uso en el tratamiento de tauopatias.
MX2024006768A (es) Compuestos y usos de los mismos.
MX2021001765A (es) Tratamiento del linfoma follicular reicindido.
ZA202110052B (en) Rebamipide for use in prevention and / or treatment of synucleinopathies
AU2020327022A8 (en) Method of treating cancer
CL2023000296A1 (es) Uso de dexpramipexol para el tratamiento del asma moderado a grave
CR20230121A (es) Tratamiento de la enfermedad de parkinson
DK1244438T3 (da) Anvendelse af beta-adrenoceptorantagonister til fremstilling af et medikament til behandling af sygdomme i den ydre nethinde
WO2022216379A8 (en) Combination therapies for the treatment of cancer
WO2022092907A3 (ko) 다부위에 적용가능한 플라즈마 치료기
WO2020097442A3 (en) Compositions and methods for the treatment of peripheral artery disease and cardiopulmonary diseases
MX2022001227A (es) Metodos de tratamiento del cancer multifocal.